Category: Oncology

This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined,  and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.

Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.

DOWNLOAD THIS BOOK FREE HERE

http://upsto.re/FgsDigh

This book provides readers with a thorough review on cervical cancer, treatment guidelines and emerging therapies available for the disease. It reviews the epidemiology clinical features, diagnosis, and medical management of cervical cancer.

Given the increasing need for preventive strategies, treatment optimization with collaborative and integrative work, this book improves the actual and integral knowledge in this neoplasm. Given the high prevalence of this disease in Latin America, this is an important text for clinicians in this region.

This book outlines the state of the art in cervical cancer treatments and is an indispensable companion for oncologists, gynecologists, surgeons and medical students.

Born Monterrey, N.L.Mexico, December 12, 1934. Studies: Medical Doctor, Universidad Autónoma de Nuevo León-, Mexico, 1952-1958; Postgraduate in Internal Medicine and Medical Oncology in South Texas Medicine School; at San Antonio Texas. USA, 1959-1964; Mayo Clinic, Rochester, Minnesota, 1965-1966.Doctor Honoris Causa granted by the Universidad Autónoma de Puebla, Doctor in Medicine-Honoris Causa., Universidad Autónoma de Nuevo León. Mexico, 11th.Cino del Duca Award, Achievement in Cancer Research” 14 th International Congress Anti-Cancer, Feb. 4, 2003.(Paris, France). Former General Director of the “Instituto Nacional de Cancerología-Mexico” (1993-2003), Distinguished Achievement Award American Society of Clinical Oncology (ASCO) Chicago, Ill Author: book Inflammatory Breast Cancer, Springer, Oct-2012, Author book Benign Disease of the Breast, Nova Publishers

 Dr. Morales, is a Medical Oncologist who developed his career as a physician at the Instituto Nacional de Cancerología (INCan), in Mexico. Professor the Oncology at Embryology Department, School of Medicine, at Universidad Nacional Autonoma de Mexico (UNAM), Assistant Profesor in the Medical Oncology at Oncology Department in the Instituto Nacional de Cancerología-UNAM.

She graduated at the “Universidad Veracruzana” as Medical Surgeon. She completed her residency in Internal Medicine

in 1997, and then continued her residency in Medical Oncology. Dr. Morales has completed a Master in Medical Sciences. She went a Oncology Observer (2004-2005) at MD Anderson Cancer Center in the Breast Cancer Department “Nelly B Conelly”. Her main research interests include Breast, Gynecologic Cancers, Fertility and Pregnancy in Patients with cancer. She has been particularly involved in the development of Oncology Clinical Research in Mexico.Born in Puebla. México, Studies Medical Doctor, Universidad Autónoma de Puebla-, Mexico, PhD. Medical School, Insti

DOWNLOAD THIS BOOK FREE HERE

http://upsto.re/FgvHFVh

This volume provides an integrated account of our current understanding of the functions of D-type cyclins during development and tumorigenesis, with special emphasis on the kinase-independent functions of these proteins. The volume will provide a thorough review of the latest discoveries on the new functions and interacting partners of mammalian cyclin Ds crucial to explain their oncogenic and differentiation properties in different cellular contexts. The volume begins with a historical perspective of how D-type cyclins were first discovered and eventually cloned from cancer tissues, followed by an account on the canonical functions of cyclin Ds during the G1-S transition of the cell cycle. Several chapters will be devoted to review the functions of D-type cyclins as transcriptional regulators and the mechanisms through which these novel functions could impact the tumorigenic process. Also discussed is emerging evidence that points to a role of D-type cyclins, particularly cyclin D1, as a cytoplasmic regulator of various cellular functions. This property, in human cells at least, is traceable to certain splice isoforms with novel oncogenic implications. Finally, a chapter is devoted to recent efforts to revise the canonical view of the “retinoblastoma pathway” to incorporate new evidence that suggests that cyclin D1’s role in G1 is to singly-phosphorylate the retinoblastoma protein (pRb) for discrimination of target protein interactions. This work represents a significant departure from the view of cyclin D1 as a negative regulator of pRb and may have critical implications for understanding the function of antineoplastic agents that target the cyclin D1-associated kinases.

This book provides up-to-date information on all aspects of ductal carcinoma in situ of the breast, including epidemiology, imaging, pathologic and biologic features, interventional diagnostics, nonpalpable lesion localization, and treatment. Surgical procedures are described in detail, covering breast conservation techniques, conservative mastectomies, breast reconstruction options, and axillary surgery. Guidance is provided on how to ensure adequacy of surgical excision and avoid local recurrence when performing breast conservation surgery and how to minimize morbidity from axillary surgery. The role and techniques of partial and whole breast irradiation are described, and the use of adjuvant systemic therapy options, including endocrine therapy and chemotherapy, is explained. A concluding chapter addresses the issue of recurrence and its current management. This book, designed for ease of consultation, will be of value for all involved in the multidisciplinary care of patients with ductal carcinoma in situ of the breast, including surgeons, medical oncologists, pathologists, radiologists, and radiotherapists.

Carlo Mariotti is Head of the Functional Unit of Breast Surgery at Ancona University Hospital and Professor of Breast Anatomy and Surgery at the Polytechnic University of the Marche Region, Ancona, Italy. Professor Mariotti graduated from Bologna University Medical School in 1979 and gained his Habilitation in Surgery in the same year. He specialized in General Surgery and Thoracic Surgery, and developed his career on the university surgery ward in Ancona. He mastered in Senologic Studies in Paris in 1984. He has since taught general surgery, clinical surgery, pathological surgery, and reconstructive surgery. He took up his present position in 2003, and since 2005 he has also been director of the National School for Breast Surgery. Professor Mariotti is a member of the Italian Surgical Society and the Italian Association of Hospital Surgeons. He has contributed to numerous research papers and scientific articles and has acted as a moderator and speaker at both national and international congresses.

DOWNLOAD THIS BOOK FREE HERE

http://upsto.re/FXSdneA

Cancer cell biology research in general, and anti-cancer drug development specifically, still relies on standard cell culture techniques that place the cells in an unnatural environment. As a consequence, growing tumor cells in plastic dishes places a selective pressure that substantially alters their original molecular and phenotypic properties.The emerging field of regenerative medicine has developed bioengineered tissue platforms that can better mimic the structure and cellular heterogeneity of in vivo tissue, and are suitable for tumor bioengineering research. Microengineering technologies have resulted in advanced methods for creating and culturing 3-D human tissue. By encapsulating the respective cell type or combining several cell types to form tissues, these model organs can be viable for longer periods of time and are cultured to develop functional properties similar to native tissues. This approach recapitulates the dynamic role of cell–cell, cell–ECM, and mechanical interactions inside the tumor. Further incorporation of cells representative of the tumor stroma, such as endothelial cells (EC) and tumor fibroblasts, can mimic the in vivo tumor microenvironment. Collectively, bioengineered tumors create an important resource for the in vitro study of tumor growth in 3D including tumor biomechanics and the effects of anti-cancer drugs on 3D tumor tissue. These technologies have the potential to overcome current limitations to genetic and histological tumor classification and development of personalized therapies.

Shay Soker, PhD, is Professor, Regenerative Medicine, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine.
Aleksander Skardal, PhD, is Assistant Professor, Regenerative Medicine and Biomedical Engineering, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine.

DOWNLOAD THIS BOOK FREE HERE

http://upsto.re/FzhMph5

This volume provides an integrated account of our current understanding of the functions of D-type cyclins during development and tumorigenesis, with special emphasis on the kinase-independent functions of these proteins. The volume will provide a thorough review of the latest discoveries on the new functions and interacting partners of mammalian cyclin Ds crucial to explain their oncogenic and differentiation properties in different cellular contexts. The volume begins with a historical perspective of how D-type cyclins were first discovered and eventually cloned from cancer tissues, followed by an account on the canonical functions of cyclin Ds during the G1-S transition of the cell cycle. Several chapters will be devoted to review the functions of D-type cyclins as transcriptional regulators and the mechanisms through which these novel functions could impact the tumorigenic process. Also discussed is emerging evidence that points to a role of D-type cyclins, particularly cyclin D1, as a cytoplasmic regulator of various cellular functions. This property, in human cells at least, is traceable to certain splice isoforms with novel oncogenic implications. Finally, a chapter is devoted to recent efforts to revise the canonical view of the “retinoblastoma pathway” to incorporate new evidence that suggests that cyclin D1’s role in G1 is to singly-phosphorylate the retinoblastoma protein (pRb) for discrimination of target protein interactions. This work represents a significant departure from the view of cyclin D1 as a negative regulator of pRb and may have critical implications for understanding the function of antineoplastic agents that target the cyclin D1-associated kinases.